Bj-005 is a humanized anti programmed death ligand 1 (PD-L1) IgG1 monoclonal antibody and human transforming growth factor β （TGF- β） A recombinant bifunctional fusion protein fused from a part of the extracellular domain of receptor II, which can simultaneously target PD-L1 and TGF- β， It is used to treat cancer patients by targeting immune checkpoints and cytokine pathways that regulate tumor cell growth to inhibit tumor growth.

Boji biology is an innovative drug R & D company, mainly engaged in the development of biological drugs for tumors and infectious diseases. The company has two R & D laboratories in San Francisco and Hangzhou, China. Since its establishment three years ago, adhering to the concept of developing global independent innovative drugs, Boji bio has begun to make layout in tumors and infectious diseases by using its biological drug R & D platform and its independently developed double antibody platform. Tumor targeted IL-5 fusion protein (bj-001), the first drug under development by Boji biology, was approved for clinical use in the United States in 2019.

The approved clinical bispecific fusion protein (bj-005) is its second independently developed product.

Dr. zhanghaizhou, co-founder and CEO of Boji biology

In response, Dr. zhanghaizhou, co-founder and CEO of Boji biomedicine, said: "our second independently developed product has been approved to enter clinical trials in the United States, which once again proves Boji biomedicine's continuous innovation ability and efficient execution. This greatly enhances the company's confidence in achieving the set goal of promoting a completely independently innovative product to clinical research every 1-2 years.

”He also said that in pd- (L) 1/tgf- β In the field of bifunctional antibody research and development, many products around the world are in the stage of clinical research and development, and joint treatment in this field is the development trend. Bj-005 and bj-001 of the company also have good synergy in anti-tumor. The company is confident that the products under development will stand out in clinical practice and benefit more patients.